Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCCR in Genetic Obesities
NCT05532020Phase 2Withdrawn
- Sponsor
- Soleno Therapeutics
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of diazoxide in Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiency, proprotein convertase 1/3 deficiency, Obesity due to SIM1 deficiency, sponsored by Soleno Therapeutics. Planned start Jan 2023; status: withdrawn.
02
Drugs
diazoxide
03
Conditions
Severe early-onset obesity-insulin resistance syndrome due to SH2B1 deficiencyproprotein convertase 1/3 deficiencyObesity due to SIM1 deficiency
Beyond the preview
Go deeper on NCT05532020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05532020.